Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study is to determine if injections of rhuFab V2 into the eye in combination with verteporfin photodynamic therapy (PDT) is a safe and efficacious treatment for patients with age-related macular degeneration.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00056823
Study type Interventional
Source Genentech, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date March 2003
Completion date December 2005

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01115387 - GARM II: A Study on the Genetics of Age-related Maculopathy
Completed NCT00775411 - Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD) Phase 2
Completed NCT00511706 - Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD) Phase 2
Completed NCT00473642 - Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Phase 4
Terminated NCT00474695 - Study Evaluating Genotypes Using Lucentis N/A
Completed NCT00759044 - Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function N/A
Recruiting NCT05752045 - OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases N/A
Completed NCT00051129 - Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD) Phase 3
Suspended NCT00460967 - Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis Phase 3
Completed NCT01024998 - Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1
Completed NCT01494805 - Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT01003691 - Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy Phase 1
Terminated NCT01577381 - Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration Phase 2
Terminated NCT01122511 - Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration Phase 2
Completed NCT00877032 - Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration Phase 1